Skip to main content

Research Repository

Advanced Search

Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions

Pacelli, A.; Greenman, J.; Cawthorne, C.; Smith, G.


A. Pacelli

C. Cawthorne

G. Smith


The role of cyclooxygenase (COX)-2 as a driving force in early tumourigenesis and the current interest in the combination of COX-2 inhibitors with standard therapy in clinical trials creates an urgent need to establish clinically relevant diagnostic tests for COX-2 expression. Molecular imaging using small-molecule probes radiolabelled for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) offers the potential to meet this need, providing a minimally invasive readout for the whole disease burden. This review summarises current approaches to the radiolabelling of small-molecule COX-2 inhibitors and their analogues for PET and SPECT imaging, and gives an overview of their biological evaluation and likely success of clinical application. © 2013 John Wiley & Sons, Ltd.


Pacelli, A., Greenman, J., Cawthorne, C., & Smith, G. (2014). Imaging COX-2 expression in cancer using PET/SPECT radioligands: current status and future directions. Journal of Labelled Compounds and Radiopharmaceuticals, 57(4), 317-322.

Journal Article Type Article
Acceptance Date Oct 29, 2013
Online Publication Date Dec 18, 2013
Publication Date 2014-04
Deposit Date Feb 25, 2016
Publicly Available Date Feb 25, 2016
Journal Journal of labelled compounds and radiopharmaceuticals
Print ISSN 0362-4803
Electronic ISSN 1099-1344
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 57
Issue 4
Pages 317-322
Keywords Coxib; Indole; Imidazole; [11C]-methylation; PET; SPECT; COX-2; Prostaglandin; Cancer; Imaging biomarker
Public URL
Publisher URL
Additional Information This is the author's accepted manuscript of an article published in Journal of labelled compounds and radiopharmaceuticals, 2014, v.57 issue 4.


You might also like

Downloadable Citations